Angiotensin system inhibitors and survival outcomes in patients with metastatic renal Cell Carcinoma

Clinical Cancer Research

Volumn 21, Issue 11, 2015, Pages 2471-2479

  McKay, Rana R ^a   Rodriguez, Gustavo E ^b   Lin, Xun ^a   Kaymakcalan, Marina D ^c   Hamnvik, Ole Petter R ^a   Sabbisetti, Venkata S ^a   Bhatt, Rupal S ^d   Simantov, Ronit ^b   Choueiri, Toni K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b PFIZER INC   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ALPHA INTERFERON; ANGIOTENSIN RECEPTOR ANTAGONIST; AXITINIB; BEVACIZUMAB; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; LOSARTAN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN INHIBITOR; ANGIOTENSIN DERIVATIVE; INDOLE DERIVATIVE; PYRROLE DERIVATIVE; RAPAMYCIN;

ABDOMINAL PAIN; AGED; ANEMIA; ANGIONEUROTIC EDEMA; ARTERY THROMBOSIS; ARTICLE; ASTHENIA; CANCER SURVIVAL; CELL VIABILITY; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DRUG RESPONSE; DRUG USE; DYSPNEA; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN CELL; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; HYPERTENSIVE CRISIS; HYPERTRIGLYCERIDEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; IN VITRO STUDY; KIDNEY FAILURE; KIDNEY METASTASIS; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; STOMATITIS; SURVIVAL PREDICTION; THROMBOCYTOPENIA; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT; ADULT; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CARCINOMA, RENAL CELL; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; DRUG EFFECTS; KAPLAN MEIER METHOD; METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT OUTCOME;

ADULT; AGED; ANGIOTENSINS; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDOLES; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; PYRROLES; RENIN-ANGIOTENSIN SYSTEM; SIROLIMUS; TREATMENT OUTCOME;

EID: 84941957570     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2332     Document Type: Article

References (42)

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke statistics-2014 update: A report from the American Heart Association. Circulation 2014;129:e28-e292.
2. Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med 1996;334:1649-54.
3. Deshayes F, Nahmias C. Angiotensin receptors: A new role in cancer? Trends Endocrinol Metab 2005;16:293-9.
4. Rosenthal T, Gavras I. Angiotensin inhibition and malignancies: A review. J Hum Hypertens 2009;23:623-35.
5. Norwood VF, Craig MR, Harris JM, Gomez RA. Differential expression of angiotensin II receptors during early renal morphogenesis. Am J Physiol 1997;272(2 Pt 2):R662-8.
6. Weerackody RP, Chatterjee PK, Mistry SK, McLaren J, Hawksworth GM, McLay JS. Selective antagonism of the AT1 receptor inhibits the effect of angiotensin II on DNA and protein synthesis of rat proximal tubular cells. Exp Nephrol 1997;5:253-62.
7. Egami K, Murohara T, Shimada T, Sasaki K, Shintani S, Sugaya T, et al. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest 2003;112:67-75.
8. Dolley-Hitze T, Jouan F, Martin B, Mottier S, Edeline J, Moranne O, et al. Angiotensin-2 receptors (AT1-R and AT2-R), new prognostic factors for renal clear-cell carcinoma? Br J Cancer 2010;103:1698-705.
9. Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 1998;352:179-84.
10. Mc Menamin UC, Murray LJ, Cantwell MM, Hughes CM. Angiotensinconverting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: A systematic review. Cancer Causes Control 2012;23:221-30.
11. Barrios CH, Hernandez-Barajas D, Brown MP, Lee SH, Fein L, Liu JH, et al. Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. Cancer 2012;118:1252-9.
12. Escudier B, Roigas J, Gillessen S, HarmenbergU, Srinivas S, Mulder SF, et al. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 2009;27:4068-75.
13. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81.
14. Hutson TE, Escudier B, Esteban E, BjarnasonGA, Lim HY, Pittman KB, et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2014;32:760-7.
15. Hutson TE, Lesovoy V, Al-Shukri S, Stus VP, Lipatov ON, Bair AH, et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: A randomised open-label phase 3 trial. Lancet Oncol 2013;14:1287-94.
16. Motzer RJ, Hutson TE, Olsen MR, Hudes GR, Burke JM, Edenfield WJ, et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol 2012;30:1371-7.
17. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24.
18. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, et al. Activity of SU11248, amultitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16-24.
19. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295: 2516-24.
20. Rini BI, Bellmunt J, Clancy J, Wang K, Niethammer AG, Hariharan S, et al. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J Clin Oncol 2014;32:752-9.
21. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial. Lancet 2011;378: 1931-9.
22. Rini BI, Melichar B, Ueda T, Grunwald V, Fishman MN, Arranz JA, et al. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: A randomised double-blind phase 2 trial. Lancet Oncol 2013;14:1233-42.
23. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
24. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17:2530-40.
25. Bendtsen F, Henriksen JH. Comparative pharmacokinetics and pharmacodynamics of lisinopril and enalapril, alone and in combination with propranolol. J Hum Hypertens 1989;3 Suppl 1:139-45.
26. Carvalho M, Oliveira CH, Mendes GD, Sucupira M, Moraes ME, De Nucci G. Amlodipine bioequivalence study: quantification by liquid chromatography coupled to tandem mass spectrometry. Biopharm Drug Dispos 2001;22:383-90.
27. Kim A, Balis FM, Widemann BC. Sorafenib and sunitinib. Oncologist 2009; 14:800-5.
28. Onoyama K, Hirakata H, Iseki K, Fujimi S, Omae T, Kobayashi M, et al. Blood concentration and urinary excretion of captopril (SQ 14, 225) in patients with chronic renal failure. Hypertension 1981;3:456-9.
29. Kaneko G, Miyajima A, Kosaka T, Mizuno R, Kikuchi E, Oya M. mTOR pathway regulates the expression of angiotensin 2 type 1 receptor in renal cell carcinoma (abstract 310). J Urol 2013;189:e126.
30. Verhoest G, Dolley-Hitze T, Jouan F, Belaud-Rotureau MA, Oger E, Lavenu A, et al. Sunitinib combinedwith angiotensin-2 type-1 receptor antagonists induces more necrosis: A murine xenograft model of renal cell carcinoma. BioMed Res Int 2014;2014:901371.
31. Keizman D, Huang P, Eisenberger MA, Pili R, Kim JJ, Antonarakis ES, et al. Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: A retrospective examination. Eur J Cancer 2011;47:1955-61.
32. Lindberg H, Nielsen D, Jensen BV, Eriksen J, Skovsgaard T. Angiotensin converting enzyme inhibitors for cancer treatment? Acta Oncol 2004;43: 142-52.
33. Uemura H, Ishiguro H, Nakaigawa N, NagashimaY, Miyoshi Y, Fujinami K, et al. Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: A possibility of tyrosine kinase inhibitor of growth factor. Mol Cancer Ther 2003;2:1139-47.
34. Zhao Y, Chen X, Cai L, Yang Y, Sui G, Fu S. Angiotensin II/angiotensin II type I receptor (AT1R) signaling promotes MCF-7 breast cancer cells survival via PI3-kinase/Akt pathway. J Cell Physiol 2010;225:168-73.
35. Kosaka T, Miyajima A, Shirotake S, Kikuchi E, HasegawaM, Mikami S, et al. Ets-1 and hypoxia inducible factor-1alpha inhibition by angiotensin II type-1 receptor blockade in hormone-refractory prostate cancer. Prostate 2010;70:162-9.
36. Araujo W, Naves M, Ravanini J, Teixeira V. Renin angiotensin system (RAS) blockade attenuates growth and metastasis formation of renal cell carcinoma in mice. Ann Oncol 2014;25 (suppl 4):iv53-iv7.
37. Hii SI, Nicol DL, Gotley DC, Thompson LC, Green MK, Jonsson JR. Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma. Br J Cancer 1998;77:880-3.
38. Miyajima A, Kosaka T, Asano T, Seta K, Kawai T, Hayakawa M. Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res 2002;62: 4176-9.
39. Huang Y, Wang Y, Li Y, Guo K, He Y. Role of sorafenib and sunitinib in the induction of expressions of NKG2D ligands in nasopharyngeal carcinoma with high expression of ABCG2. J Cancer Res Clin Oncol 2011;137: 829-37.
40. Bair SM, Choueiri TK, Moslehi J. Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives. Trends Cardiovasc Med 2013;23:104-13.
41. Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011;103: 763-73.
42. Rini BI, Schiller JH, Fruehauf JP, Cohen EE, Tarazi JC, Rosbrook B, et al. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res 2011;17:3841-9.